Pancreatic Ductal Adenocarcinoma: State-of-the-Art 2017 and New Therapeutic Strategies

The most common malignant cancer arising from the pancreas is pancreatic ductal adenocarcinoma (PDAC). PDAC has a major public health impact as it is the fourth-leading cause of cancer-related death, with approximately 53,670 new cases and 43,090 deaths anticipated in 2017 in the US[1]. This latter number is projected to increase and before 2030 PDAC is anticipated to be the second-leading cause of cancer-related deaths second only to lung cancer[2]. More than a half of patients with PDAC present with locally advanced or metastatic disease at diagnosis, with the main metastatic sites being the liver, the lungs and the peritoneum, limiting therapeutic options to systemic therapy and optimal supportive care with the aim to induce disease regression, extend life and alleviate symptoms[1].

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vqy3Fv
via IFTTT